Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma

被引：11

作者：

Amann, V. C. ^{[1
,2
]}

Hoffmann, D. ^{[3
]}

Mangana, J. ^{[1
]}

Dummer, R. ^{[1
]}

Goldinger, S. M. ^{[1
]}

机构：

[1] Univ Zurich Hosp, Dept Dermatol, Zurich, Switzerland

[2] Kantonsspital Aarau, Univ Dept Med, Aarau, Switzerland

[3] Herrenberg Hosp, Dept Gynecol & Obstet, Herrenberg, Germany

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2017年 / 31卷 / 10期

关键词：

VEMURAFENIB; RECHALLENGE; RESISTANCE; DABRAFENIB;

D O I：

10.1111/jdv.14268

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

BackgroundThe combination treatment with BRAF and MEK inhibitors is amongst the current standard of care for stage IIIC/IV BRAF-mutated melanoma. However, therapeutic options are limited once patients have progressed upon both targeted and immunotherapy. ObjectiveTo investigate whether retreatment with BRAF and MEK inhibitor combination is an option for patients with metastatic BRAF-mutated melanoma upon previous progression on kinase inhibitors. MethodsTwo patients with metastatic BRAF-mutated melanoma were rechallenged with BRAF and MEK inhibitor combination after progression on targeted therapy and subsequent immunotherapy with anti-CTLA-4 and anti-PD-1 antibodies. ResultsBoth patients responded to retreatment. Responses were limited to a few months and associated with a considerable increase in quality of life. ConclusionRetreatment with BRAF and MEK inhibitors may present a feasible treatment option upon progression on both kinase inhibitors and immunotherapy, and should be considered when all other treatment options have been exhausted.

引用

页码：1638 / 1640

页数：3

共 9 条

[1] Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance [J].

Das Thakur, Meghna ;

Salangsang, Fernando ;

Landman, Allison S. ;

Sellers, William R. ;

Pryer, Nancy K. ;

Levesque, Mitchell P. ;

Dummer, Reinhard ;

McMahon, Martin ;

Stuart, Darrin D. .

NATURE, 2013, 494 (7436) :251-255

[2] Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma [J].

Larkin, James ;

Ascierto, Paolo A. ;

Dreno, Brigitte ;

Atkinson, Victoria ;

Liszkay, Gabriella ;

Maio, Michele ;

Mandala, Mario ;

Demidov, Lev ;

Stroyakovskiy, Daniil ;

Thomas, Luc ;

de la Cruz-Merino, Luis ;

Dutriaux, Caroline ;

Garbe, Claus ;

Sovak, Mika A. ;

Chang, Ilsung ;

Choong, Nicholas ;

Hack, Stephen P. ;

McArthur, Grant A. ;

Ribas, Antoni .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (20) :1867-1876

[3] Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial [J].

Long, Georgina V. ;

Stroyakovskiy, Daniil ;

Gogas, Helen ;

Levchenko, Evgeny ;

de Braud, Filippo ;

Larkin, James ;

Garbe, Claus ;

Jouary, Thomas ;

Hauschild, Axel ;

Grob, Jean-Jacques ;

Chiarion-Sileni, Vanna ;

Lebbe, Celeste ;

Mandala, Mario ;

Millward, Michael ;

Arance, Ana ;

Bondarenko, Igor ;

Haanen, John B. A. G. ;

Hansson, Johan ;

Utikal, Jochen ;

Ferraresi, Virginia ;

Kovalenko, Nadezhda ;

Mohr, Peter ;

Probachai, Volodymr ;

Schadendorf, Dirk ;

Nathan, Paul ;

Robert, Caroline ;

Ribas, Antoni ;

DeMarini, Douglas J. ;

Irani, Jhangir G. ;

Swann, Suzanne ;

Legos, Jeffrey J. ;

Jin, Fan ;

Mookerjee, Bijoyesh ;

Flaherty, Keith .

LANCET, 2015, 386 (9992) :444-451

[4] Resistance to Vemurafenib Can Be Reversible After Treatment Interruption A Case Report of a Metastatic Melanoma Patient [J].

Mackiewicz-Wysocka, Malgorzata ;

Krokowicz, Lukasz ;

Kocur, Jacek ;

Mackiewicz, Jacek .

MEDICINE, 2014, 93 (27)

[5] Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib [J].

Robert, Caroline ;

Karaszewska, Boguslawa ;

Schachter, Jacob ;

Rutkowski, Piotr ;

Mackiewicz, Andrzej ;

Stroiakovski, Daniil ;

Lichinitser, Michael ;

Dummer, Reinhard ;

Grange, Florent ;

Mortier, Laurent ;

Chiarion-Sileni, Vanna ;

Drucis, Kamil ;

Krajsova, Ivana ;

Hauschild, Axel ;

Lorigan, Paul ;

Wolter, Pascal ;

Long, Georgina V. ;

Flaherty, Keith ;

Nathan, Paul ;

Ribas, Antoni ;

Martin, Anne-Marie ;

Sun, Peng ;

Crist, Wendy ;

Legos, Jeff ;

Rubin, Stephen D. ;

Little, Shonda M. ;

Schadendorf, Dirk .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (01) :30-39

[6] Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression [J].

Romano, Emanuela ;

Pradervand, Sylvain ;

Paillusson, Alexandra ;

Weber, Johann ;

Harshman, Keith ;

Muehlethaler, Katja ;

Speiser, Daniel ;

Peters, Solange ;

Rimoldi, Donata ;

Michielin, Olivier .

CLINICAL CANCER RESEARCH, 2013, 19 (20) :5749-5757

[7] BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma [J].

Roux, Jennifer ;

Pages, Cecile ;

Malouf, Diane ;

Seguin, Nicole Basset ;

Madjlessi, Nika ;

Baccard, Michel ;

Comte, Christelle ;

Archimbaud, Alain ;

Battistella, Maxime ;

Viguier, Manuelle ;

Mourah, Samia ;

Bagot, Martine ;

Lebbe, Celeste .

MELANOMA RESEARCH, 2015, 25 (06) :559-563

[8] Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor [J].

Seghers, Amelie Clementine ;

Wilgenhof, Sofie ;

Lebbe, Celeste ;

Neyns, Bart .

MELANOMA RESEARCH, 2012, 22 (06) :466-472

[9] Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial [J].

Weber, Jeffrey S. ;

D'Angelo, Sandra P. ;

Minor, David ;

Hodi, F. Stephen ;

Gutzmer, Ralf ;

Neyns, Bart ;

Hoeller, Christoph ;

Khushalani, Nikhil I. ;

Miller, Wilson H., Jr. ;

Lao, Christopher D. ;

Linette, Gerald P. ;

Thomas, Luc ;

Lorigan, Paul ;

Grossmann, Kenneth F. ;

Hassel, Jessica C. ;

Maio, Michele ;

Sznol, Mario ;

Ascierto, Paolo A. ;

Mohr, Peter ;

Chmielowski, Bartosz ;

Bryce, Alan ;

Svane, Inge M. ;

Grob, Jean-Jacques ;

Krackhardt, Angela M. ;

Horak, Christine ;

Lambert, Alexandre ;

Yang, Arvin S. ;

Larkin, James .

LANCET ONCOLOGY, 2015, 16 (04) :375-384

← 1 →